Mustjoki S - Search Results

1

Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients.

Brück O, Lee MH, Turkki R, Uski I, Penttilä P, Paavolainen L, Kovanen P, Järvinen P, Bono P, Pellinen T, Mustjoki S, Kreutzman A. Brück O, et al. Among authors: mustjoki s. Mod Pathol. 2021 Dec;34(12):2229-2241. doi: 10.1038/s41379-021-00864-0. Epub 2021 Jul 2. Mod Pathol. 2021. PMID: 34215851 Free PMC article.

2

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S. Kreutzman A, et al. Among authors: mustjoki s. Blood. 2010 Aug 5;116(5):772-82. doi: 10.1182/blood-2009-12-256800. Epub 2010 Apr 22. Blood. 2010. PMID: 20413659 Free article.

3

Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy.

Jalkanen SE, Vakkila J, Kreutzman A, Nieminen JK, Porkka K, Mustjoki S. Jalkanen SE, et al. Among authors: mustjoki s. Exp Hematol. 2011 Jan;39(1):102-113.e1. doi: 10.1016/j.exphem.2010.09.005. Epub 2010 Oct 12. Exp Hematol. 2011. PMID: 20869423

4

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, Melo T, Einsele H, Porkka K, Price DA, Mustjoki S, Seggewiss R. Kreutzman A, et al. Among authors: mustjoki s. Leukemia. 2011 Oct;25(10):1587-97. doi: 10.1038/leu.2011.135. Epub 2011 Jun 7. Leukemia. 2011. PMID: 21647156

5

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.

Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V, Voglová J, Sinisalo M, Flochová E, Vakkila J, Arstila P, Porkka K, Mustjoki S. Kreutzman A, et al. Among authors: mustjoki s. PLoS One. 2011;6(8):e23022. doi: 10.1371/journal.pone.0023022. Epub 2011 Aug 9. PLoS One. 2011. PMID: 21857985 Free PMC article.

6

Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.

Kreutzman A, Jaatinen T, Greco D, Vakkila E, Richter J, Ekblom M, Hjorth-Hansen H, Stenke L, Melo T, Paquette R, Seggewiss-Bernhardt R, Guerci-Bresler A, Talbot A, Cayuela JM, Mahon FX, Porkka K, Lipton J, Partanen J, Rousselot P, Mustjoki S. Kreutzman A, et al. Among authors: mustjoki s. Exp Hematol. 2012 Nov;40(11):906-913.e1. doi: 10.1016/j.exphem.2012.07.007. Epub 2012 Jul 25. Exp Hematol. 2012. PMID: 22842045 Free article.

7

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen AM, Hautaniemi S, Bouchet S, Molimard M, Smykla R, Lee FY, Vakkila J, Jalkanen S, Salmi M, Porkka K. Mustjoki S, et al. Leukemia. 2013 Apr;27(4):914-24. doi: 10.1038/leu.2012.348. Epub 2012 Nov 29. Leukemia. 2013. PMID: 23192016

8

Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.

Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila E, Räsänen A, Vapaatalo M, Remes K, Lundán T, Hjorth-Hansen H, Vakkila J, Simonsson B, Mustjoki S, Porkka K. Koskenvesa P, et al. Among authors: mustjoki s. Eur J Haematol. 2014;92(5):413-20. doi: 10.1111/ejh.12258. Epub 2014 Jan 28. Eur J Haematol. 2014. PMID: 24372965

9

Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.

Ilander M, Kreutzman A, Rohon P, Melo T, Faber E, Porkka K, Vakkila J, Mustjoki S. Ilander M, et al. Among authors: mustjoki s. PLoS One. 2014 Jan 31;9(1):e87794. doi: 10.1371/journal.pone.0087794. eCollection 2014. PLoS One. 2014. PMID: 24498197 Free PMC article. Clinical Trial.

10

IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia.

Ilander M, Kreutzman A, Mustjoki S. Ilander M, et al. Among authors: mustjoki s. Oncoimmunology. 2014 Apr 29;3:e28781. doi: 10.4161/onci.28781. eCollection 2014. Oncoimmunology. 2014. PMID: 25050224 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

209 results

Search Page